Unintended Pregnancies Soar as Women on Popular Weight-Loss Medications Overlook Contraception, Raising Alarms Over Fetal Safety

Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers. This urgent call to action stems from a new study published in the Medical Journal of Australia, which starkly reveals that the vast majority of Australian women of reproductive age prescribed GLP-1 receptor agonists – a class of drugs increasingly utilised for weight loss, exemplified by medications such as Ozempic – are not employing effective contraception, despite well-documented warnings and potential teratogenic risks during gestation. The findings underscore a critical gap in clinical practice and patient counselling, potentially exposing a growing cohort of pregnancies to uncertain developmental outcomes and necessitating immediate attention from healthcare providers, policymakers, and the pharmaceutical industry.

The Rise of GLP-1s and a Hidden Health Crisis

The research, which meticulously analysed data from over 1.6 million women aged 18 to 49 who attended general practices across Australia between 2011 and 2022, paints a concerning picture. Out of the 18,010 women who initiated GLP-1 receptor agonist treatment during this period, a staggering 79% reported no use of contraception. This widespread oversight is particularly alarming given the rapid expansion of GLP-1s beyond their original indication for type 2 diabetes management into the lucrative and highly sought-after weight-loss market. Originally developed to enhance glycemic control by mimicking the natural hormone GLP-1, these medications, including semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda), have demonstrated profound appetite-suppressing and weight-loss effects, leading to an explosion in their off-label and on-label prescriptions for obesity.

Associate Professor Luke Grzeskowiak, a pharmacist and lead author of the study from Flinders University’s College of Medicine and Public Health, articulated the gravity of the situation. "We’re seeing widespread use of these medications among women of childbearing age, but very little evidence that contraception is being considered as part of routine care," he stated. Highlighting the scale of this shift, Associate Professor Grzeskowiak noted that in 2022 alone, more than 6,000 women commenced treatment on GLP-1s, with over 90% of these individuals not possessing a diabetes diagnosis. This demographic transition, from a clinical population often managed with careful monitoring, to a broader, healthy population primarily seeking aesthetic or lifestyle improvements, has introduced new challenges regarding patient education and risk management. While acknowledging the potential benefits of these medications, Grzeskowiak firmly cautioned, "These medications can be incredibly helpful, but they’re not risk-free, especially during pregnancy."

A Chronology of Concern: From Diabetes to Weight Loss to Pregnancy Risks

The journey of GLP-1 receptor agonists began in the early 2000s, with the first drug in this class, exenatide, gaining FDA approval for type 2 diabetes in 2005. Over the subsequent decade, newer and more potent analogues emerged, notably liraglutide and semaglutide, offering superior glucose control and, significantly, substantial weight loss as a beneficial side effect. By the mid-2010s, the potential for these drugs as dedicated weight-loss therapies became undeniable, leading to regulatory approvals for specific agents like liraglutide (Saxenda) in 2014 and semaglutide (Wegovy) in 2021 for chronic weight management in individuals with obesity or overweight with comorbidities.

As their popularity surged, particularly for their transformative weight-loss capabilities, so did the imperative for understanding their safety profile across all patient populations. The period covered by the Flinders study, 2011 to 2022, directly correlates with this exponential growth and diversification of GLP-1 usage. During this time, anecdotal reports and early clinical observations began to raise flags regarding potential pregnancy risks. While comprehensive human data remains limited due to ethical constraints on conducting trials in pregnant women, preclinical animal studies have provided early, albeit concerning, signals. A review of animal studies conducted by the University of Amsterdam, for instance, linked GLP-1 exposure during pregnancy to reduced fetal growth and skeletal abnormalities. These findings, while not directly translatable to humans, underscore a strong precautionary principle that dictates rigorous avoidance of these medications during pregnancy.

The timeline of evolving clinical guidance also highlights the lag in consistent practice. While regulatory bodies in some jurisdictions, such as the UK, have explicitly advised women using GLP-1 receptor agonists to avoid pregnancy and utilise effective contraception, the Flinders study demonstrates that this crucial advice is not being followed consistently in Australian clinical practice. This disparity points to systemic issues in information dissemination, physician awareness, and patient counselling that require urgent rectification.

Unintended Pregnancies: The Sobering Statistics

The study’s data on unintended pregnancies further amplifies the urgency of the researchers’ warnings. It found that a concerning 2.2% of women became pregnant within six months of initiating GLP-1 treatment. This rate, while seemingly low, translates to a significant number of potentially exposed pregnancies given the vast number of women now taking these medications. The pregnancy rates were notably highest among younger women with diabetes, suggesting that improved metabolic control might enhance fertility, and among women without diabetes in their early thirties, a demographic often actively considering or attempting conception.

A particularly insightful finding was the twofold increased likelihood of conception among women with polycystic ovary syndrome (PCOS). PCOS is a common endocrine disorder associated with insulin resistance and often contributes to infertility and weight gain. The weight loss achieved through GLP-1 agonists may improve hormonal balance and ovulation in these women, thereby unintentionally increasing their fertility. While improved fertility can be a desired outcome for many with PCOS, when it occurs during GLP-1 treatment without adequate contraception, it transforms into an unintended and potentially risky consequence.

Crucially, the study provided clear evidence that effective contraception mitigates this risk: women who were using contraception at the time of prescribing had a significantly lower risk of pregnancy. This simple yet powerful correlation underscores that the solution lies not just in awareness of risks, but in the proactive implementation of contraception as a routine part of GLP-1 prescribing for women of reproductive age.

Broader Implications: A Call for Systemic Change

The findings from Flinders University resonate across several critical domains: public health, clinical practice, regulatory oversight, and pharmaceutical responsibility.

Public Health Imperatives: The primary concern for public health revolves around the potential for an increase in adverse pregnancy outcomes. If animal study findings have any parallel in human gestation, the continued unmonitored use of GLP-1s could lead to a rise in congenital anomalies or complications. This necessitates proactive public health campaigns aimed at educating women of reproductive age about the risks of GLP-1s during pregnancy and the paramount importance of contraception. Such campaigns must be clear, accessible, and reach diverse populations, including those who may be obtaining these medications through less formal channels.

Clinical Practice Overhaul: The study exposes a critical gap in routine clinical care. General practitioners and other prescribing healthcare professionals must integrate robust reproductive health counselling into every consultation where GLP-1s are considered for women of childbearing potential. This includes:

• Comprehensive Risk-Benefit Discussions: Clearly outlining the known and potential risks of GLP-1s in pregnancy.
• Contraception Assessment: Thoroughly assessing current contraceptive use and efficacy, and proactively discussing highly effective methods (e.g., long-acting reversible contraceptives like IUDs or implants) if not already in use.
• Pregnancy Planning: Advising women to discontinue GLP-1s for a recommended period (often 2-3 months) before attempting conception, allowing the drug to clear the system.
• Shared Decision-Making: Empowering women to make informed choices about their treatment in the context of their reproductive goals.
  Associate Professor Grzeskowiak emphasised this point: "We need to ensure that reproductive health is part of every conversation when these drugs are prescribed to any women of childbearing age."

Regulatory and Guideline Enhancements: The discrepancies highlighted by the study between international best practice (e.g., UK advice) and Australian clinical reality point to a need for clearer, more explicit national guidelines. Australian regulatory bodies, such as the Therapeutic Goods Administration (TGA), alongside professional organisations like the Royal Australian College of General Practitioners (RACGP) and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), should collaborate to develop and disseminate unambiguous practice recommendations for prescribers. These guidelines should specify requirements for pre-prescription counselling, documentation of contraceptive use, and clear protocols for managing unintended pregnancies during treatment. "It is also vitally important that we have clearer practice recommendations and guidelines for those prescribing GLP-1s to women to ensure their safe and effective use," Grzeskowiak asserted.

Pharmaceutical Industry Responsibility: While pharmaceutical companies include warnings in product information, the sheer volume of off-label prescribing for weight loss and the rapid uptake of these drugs mean that these warnings may not always reach patients effectively. Manufacturers have a responsibility to support educational initiatives for healthcare providers and ensure that patient information leaflets are explicit about pregnancy risks and the need for contraception.

The Economic and Social Context: The burgeoning market for GLP-1s also operates within a broader context of the global obesity epidemic. With over one-third of the global adult population classified as overweight or obese, and significant societal pressure to manage weight, the demand for effective pharmacological interventions is immense. This demand, while understandable, must not overshadow the fundamental principles of patient safety, particularly for women who represent a significant portion of this demographic. The accessibility and affordability of both GLP-1s and effective contraception also raise questions of equity and healthcare access.

Looking Ahead: The Need for Ongoing Research

The Flinders University study is a crucial step in highlighting an emerging public health challenge, but it also underscores the limitations of current knowledge. As Associate Professor Grzeskowiak noted, while animal data exists, human data regarding the impact of GLP-1s on pregnancy and unborn babies is still limited. Therefore, further observational studies and pharmacovigilance efforts are warranted to gather more definitive evidence on specific risks. These studies should track pregnancy outcomes in women exposed to GLP-1s to determine the exact nature and prevalence of any adverse effects. Long-term follow-up of children exposed in utero would also be invaluable.

In conclusion, the Flinders University research serves as a potent reminder of the complexities inherent in the rapid adoption of new pharmacological treatments. While GLP-1 receptor agonists offer significant promise for weight management and metabolic health, their widespread use demands a renewed focus on comprehensive patient care, particularly for women of reproductive age. The onus is now on prescribers, patients, regulatory bodies, and public health advocates to ensure that the transformative potential of these medications is realised without compromising the safety and well-being of future generations. The advice remains clear: "Speak to your GP about the risks and benefits of GLP-1 medicines before taking them, and only take those prescribed by a healthcare professional." This dialogue must explicitly include a robust discussion about contraception and pregnancy planning to avert what could become a significant public health crisis.

Acknowledgements: This pivotal research was supported by salary support to Luke Grzeskowiak from a Channel 7 Children’s Research Foundation Fellowship (CRF-210323). The authors also acknowledge the invaluable contributions of members of the SPHERE Centre of Research Excellence in Women’s Sexual and Reproductive Health in Primary Care (SPHERE 2.0 CRE), which is funded by the National Health and Medical Research Council (APP2024717).